Previous 10 | Next 10 |
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
BeiGene ( NASDAQ: BGNE ) and Novartis' ( NYSE: NVS ) tislelizumab met the main goal of being as good as Bayer's ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) Nexavar (sorafenib) in improving overall survival (OS) of patients with a type of liver cancer in a phase 3 trial...
Trial met primary endpoint of non-inferior overall survival versus sorafenib Results mark eighth positive Phase 3 trial readout for tislelizumab across multiple cancer types and lines of therapy Data to be submitted for presentation at upcoming medical conference ...
U.S.-listed shares of BeiGene ( NASDAQ: BGNE ) rose as much as 8.9% to $184.8 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y. BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET. BGN...
BeiGene press release ( NASDAQ: BGNE ): Q2 GAAP EPADS of -$5.56 misses by $1.45 . Revenue of $341.57M (+127.7% Y/Y) beats by $30.5M . Cash, cash equivalents, restricted cash, and short-term investments were $5.7B as of June 30, 2022 and $6.6B as of December 31,...
Recorded product revenue of $304.5 million for the second quarter, representing a 120% increase from $138.6 million in the prior year period BRUKINSA product revenue increased 203% globally versus the second quarter of 2021, and 23% sequentially compared to the first qua...
Alibaba ( NYSE: BABA ) rose on Monday after the Chinese internet company said it would "strive" to keep its New York listing as the Securities and Exchange Commission said it may delist the company amid auditing concerns. Alibaba ( BABA ) said that it would “conti...
Today, we take a look at Zymeworks which recently was the target of a takeover attempt. The company has a new leadership team and is advancing its lead candidate via two pivotal trials. An investment analysis follows in the paragraphs below. Those who can make people...
The U.S. Food and Drug Administration (FDA) deferred action on approving BeiGene ( NASDAQ: BGNE ) and Novartis' ( NYSE: NVS ) tislelizumab for esophageal cancer as the agency was unable to carry out required inspections in China due to COVID-19 related travel ...
FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on develop...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...